Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

23.91USD
15 Dec 2017
Change (% chg)

$-0.38 (-1.56%)
Prev Close
$24.29
Open
$24.31
Day's High
$24.65
Day's Low
$22.68
Volume
332,349
Avg. Vol
108,619
52-wk High
$39.26
52-wk Low
$16.43

Chart for

About

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $794.45
Shares Outstanding(Mil.): 22.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln ‍​

* Files for mixed shelf of up to $150 million - SEC filing‍​ Source text : [http://bit.ly/2zK9cPg] Further company coverage:

27 Oct 2017

BRIEF-La Jolla reports Q3 loss $1.19/shr

* La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress

26 Oct 2017

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

* Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍ Source text : [http://bit.ly/2g07Ckv] Further company coverage:

10 Oct 2017

BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501

* La Jolla Pharmaceutical Company announces intent to submit Marketing Authorization Application for LJPC-501 in the third quarter of 2018 Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501

* La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501

28 Aug 2017

BRIEF-La Jolla Pharma ‍announces launch of expanded access program for LJPC-501​

* La Jolla Pharmaceutical Co - ‍announces launch of expanded access program for LJPC-501​ Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-La Jolla Pharmaceutical reports CEO compensation

* CEO George Tidmarsh's 2016 total compensation was $4.7 million versus $15.6 million in 2015 - SEC filing Source text for Eikon: Further company coverage:

31 Jul 2017

BRIEF-La Jolla quarterly loss per share $1.21

* La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2017 and recent corporate progress

27 Jul 2017

Competitors

  Price Chg
Galectin Therapeutics Inc (GALT.OQ) $2.35 -0.04
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Novartis AG (NOVN.S) CHF83.80 -0.05
Celltrion, Inc. (068270.KQ) ₩210,500.00 +1,000.00
Kyowa Hakko Kirin Co Ltd (4151.T) ¥2,159 -5.00
Astellas Pharma Inc (4503.T) ¥1,432 -20.00

Earnings vs. Estimates